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68* Evaluation of new guidelines for the eradication of Staphylococcus
aureus in children with cystic ﬁbrosis
I. Aldag, C.J. Taylor, P. Fenton, N.S. West. CF Unit, Shefﬁeld Children’s Hospital,
Shefﬁeld, United Kingdom
Introduction: Staphylococcus aureus (S. aureus) is a major cause of pulmonary
infection in CF patients. In 2004 our unit introduced more aggressive antibiotic
treatment guidelines. Every episode of S. aureus growth received at least 4 weeks
oral treatment with ﬂucloxacillin or co-amoxiclav with the addition of a second anti-
staphylococcal if growth persisted after 2 weeks. This was combined with attempted
eradication of nasal carriage using topical agents. Increases in Pseudomonas
aeruginosa isolation were closely monitored due to concerns about long term anti-
staphylococcal usage.
Methods: Patient records of all patients growing S. aureus in the year 2004 were
retrospectively reviewed. Data on adherence to the guidelines, successful eradication
of S. aureus, lung function parameters and P. aeruginosa isolation were collected.
Results: 109 episodes of S. aureus growth in 53 patients were identiﬁed. Adherence
to the guidelines was 96%. There was successful eradication of S. aureus in 78% of
cases. Time to re-growth varied from 6−60 weeks (mean 26 weeks). FEV1 improved
by a mean of 6.6% following eradication therapy. P. aeruginosa isolation rate for
2004 remained static.
Conclusion: With the introduction and implementation of aggressive anti-
staphylococcal therapy good eradication rates of S. aureus were achieved and
sustained. There has been no demonstrable increase in P. aeruginosa isolation to
date. A longer observation period is required to identify further risks and beneﬁts.
69 Healthcare costs of infection with the major transmissible UK
Pseudomonas aeruginosa strain, LES
E. Spencer-Clegg, K. Mohan, J. McWean, M. Day, A. Youzguin, M.J. Ledson,
M.J. Walshaw. Regional Adult CF Unit, The Cardiothoracic Centre, Liverpool,
United Kingdom.
The Liverpool epidemic strain of Pseudomonas aeruginosa (LES) is widespread
throughout UK CF clinics, and as well as exhibiting greater resistance to antibi-
otics than other strains, we have shown it to cause increased morbidity (Thorax
2004;59:334−6). To assess the effect this has on consumption of health care
resources within the CF community, we compared the need for IV antibiotics in
our cohort of 127 LES patients with the 70 infected with unique Pseudomonas
aeruginosa strains attending our large CF unit over a 6 month period (Jan-Jun
2006). The two groups had a similar age (mean 24 years [range 17 to 51] versus 25
[18 to 49]) and spirometry (mean FEV1%: 66 [20 to 132] v 73 [22 to 128]; t = 0.98,
P =NS). More LES patients required IV treatment (71 v 21, c2 = 10.84, P< 0.001)
but the proportion given outpatient IVs was similar (29 episodes in 24 patients v
16/11, P =NS). However, more LES patients required inpatient IV therapy (62 v 16,
c2 = 12.71, P< 0.001), and although the number of courses was not proportionally
greater, LES patients spent longer in hospital each time (average 13.8 days versus
11.2, P< 0.02). A wide range of different antipseudomonal antibiotics were used
for each group both as inpatients and outpatients.
Thus, we have shown that patients infected with LES not only require more
treatment than the remainder, but that more of this treatment needs to be given
in hospital. As a result of this, LES patients consume more bed days (average
22.2 per infected patient per year) than those infected with unique Pseudomonas
aeruginosa strains (average 6.8 per patient per year), underlining the need to prevent
cross infection with this organism in the CF community.
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Antipseudomonal therapy at the time of early Pseudomonas aeruginosa
(PA)infection has been used in CF patients in order to try to eradicate this pathogen
but the optimal drug regimen is not established.
Objectives: Evaluate the rate of eradication of initial PA isolation in CF patients
that received systemic and inhaled antibiotics following a standard protocol.
Material and Methods: Between Feb/04 and Jan/07 sixteen patients, 9M/7F, were
evaluated in their ﬁrst PA isolation. The eradication protocol consisted of: step I (1st
isolation) = 3 weeks of ciproﬂoxacin or intravenous antibiotics + inhaled gentamicin
or colistin for 3 to 6 weeks; step II (2nd isolation) = 3 weeks of ciproﬂoxacin
or intravenous antibiotics + inhaled gentamicin or colistin for 12 weeks; step III
(3rd isolation) = 6 weeks of ciproﬂoxacin + 6 months of inhaled gentamicin or
colistin. Oropharyngeal swabs or sputum cultures were performed approximately
every 2 months.
Results: Median age at ﬁrst PA isolation was 17 months (age range 4m to 13 y).
Four patients received only step I, four received step II and eight received step III
treatment. P. aeruginosa cultures post treatment were negative in 12 patients, for a
period between 4 to 33 months (median of 12m).
Conclusions: The ﬁrst PA isolation occured in very young patients. Most patients
needed more than one treatment and this led to a PA free-period in 75% of the
patients, although the follow up in many of these patients is still short. The early
age of PA acquisition among our patients is a concern and long term follow up will
be crucial to evaluate if this eradication protocol will be effective in postponing
chronic PA infection.
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Paediatrics, University of Florence, Cystic Fibrosis Center, Florence, Italy
Eradication of Pseudomonas aeruginosa (Pa) at ﬁrst isolation is possible with early
antibiotic treatment. Patients who have successfully undergone eradication can be
re-colonised in which case it remains to be determined whether it consists in re-
growth of the same suppressed strain, or re-colonisation by a new strain.
The aim of this study was to investigate the clonal relatedness between Pa isolates
in order to distinguish successful eradication (re-colonisation) from unsuccessful
(re-growth), by comparing the genetic relatedness among Pa strains isolated before
and after an eradication period.
Eradication treatment was evaluated using immunological and microbiological
criteria (at least 3 consecutive negative respiratory cultures over a 6-month period
indicating that the organism had been eradicated), and molecular methods by RAPD
analysis.
After successful eradication treatment, all 26 patients were newly colonised by Pa
in the study period (1998–2005), for a total of 39 new isolations.
Based on microbiological/immunological and molecular criteria, eradication was
obtained in 32 (82%) and 28 (71.8%) of 39 colonisations respectively. Therefore
4 (10.2%) out of 39 colonisations were re-growth.
Molecular techniques can improve monitoring of eradication therapy, showing that
antibiotic treatment has been successfully performed, however, the prevalence of
true eradication is slightly lower when evaluated by genotypic criteria.
